Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms SAR 440234, SAR440234 |
Target |
Action modulators, stimulants |
Mechanism CD123 modulators(Interleukin-3 receptor subunit alpha modulators), CD3 stimulants(T cell surface glycoprotein CD3 stimulants) |
Therapeutic Areas |
Active Indication- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
High Risk Myelodysplastic Syndrome | Phase 2 | United States | 24 Oct 2018 | |
High Risk Myelodysplastic Syndrome | Phase 2 | France | 24 Oct 2018 | |
Pre B-cell acute lymphoblastic leukemia | Phase 2 | United States | 24 Oct 2018 | |
Pre B-cell acute lymphoblastic leukemia | Phase 2 | France | 24 Oct 2018 | |
Refractory acute myeloid leukemia | Phase 2 | United States | 24 Oct 2018 | |
Refractory acute myeloid leukemia | Phase 2 | France | 24 Oct 2018 |
Phase 1/2 | 7 | crqnkwblvi = sorzqnjglq kqifnfhaer (dxoosvkqva, advdvtiiev - nctkcmyelg) View more | - | 07 Apr 2022 |